EA201891570A1 - Способ подавления фиброза у нуждающегося в этом субъекта - Google Patents

Способ подавления фиброза у нуждающегося в этом субъекта

Info

Publication number
EA201891570A1
EA201891570A1 EA201891570A EA201891570A EA201891570A1 EA 201891570 A1 EA201891570 A1 EA 201891570A1 EA 201891570 A EA201891570 A EA 201891570A EA 201891570 A EA201891570 A EA 201891570A EA 201891570 A1 EA201891570 A1 EA 201891570A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fibrosis
subject
methods
relates
supporting
Prior art date
Application number
EA201891570A
Other languages
English (en)
Inventor
Найджел Джон Бранскилл
Грегори А. Демопулос
Томас Дадлер
Ханс-Вильхельм Швебле
Original Assignee
Юниверсити Оф Лестер
Омерос Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Лестер, Омерос Корпорейшн filed Critical Юниверсити Оф Лестер
Publication of EA201891570A1 publication Critical patent/EA201891570A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В одном из аспектов изобретение относится к способам лечения, подавления, облегчения или профилактики фиброза у млекопитающего, страдающего или имеющего риск развития заболевания или расстройства, вызванного или осложненного фиброзом и/или воспалением. В одном из вариантов осуществления изобретение относится к способам лечения субъекта, страдающего фиброзом почек. В одном из вариантов осуществления настоящее изобретение относится к способам уменьшения протеинурии у субъекта, страдающего заболеванием или состоянием почек, ассоциированным с протеинурией. Способы включают этап введения нуждающемуся в этом субъекту количества ингибирующего MASP-2 агента, эффективного для подавления MASP-2-зависимой активации комплемента.
EA201891570A 2016-01-05 2017-01-05 Способ подавления фиброза у нуждающегося в этом субъекта EA201891570A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275025P 2016-01-05 2016-01-05
US201662407979P 2016-10-13 2016-10-13
PCT/US2017/012345 WO2017120344A1 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof

Publications (1)

Publication Number Publication Date
EA201891570A1 true EA201891570A1 (ru) 2018-12-28

Family

ID=59236184

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891570A EA201891570A1 (ru) 2016-01-05 2017-01-05 Способ подавления фиброза у нуждающегося в этом субъекта

Country Status (21)

Country Link
US (2) US10736960B2 (ru)
EP (1) EP3400012A4 (ru)
JP (3) JP6682653B2 (ru)
KR (4) KR102475622B1 (ru)
CN (3) CN108495652A (ru)
AU (4) AU2017205453B2 (ru)
BR (1) BR112018013723A2 (ru)
CA (2) CA3185172A1 (ru)
CL (3) CL2018001817A1 (ru)
EA (1) EA201891570A1 (ru)
GE (1) GEP20217290B (ru)
IL (2) IL294411A (ru)
MA (1) MA43591A (ru)
MX (2) MX2018008331A (ru)
MY (1) MY194810A (ru)
NZ (1) NZ744629A (ru)
PH (1) PH12018501435A1 (ru)
SG (2) SG11201805695SA (ru)
UA (1) UA127339C2 (ru)
WO (1) WO2017120344A1 (ru)
ZA (1) ZA201805238B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101141544B1 (ko) 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법
CN108026527B (zh) 2015-06-15 2022-05-10 Mpeg La有限责任公司 确定的多偶联寡核苷酸
UA127339C2 (uk) 2016-01-05 2023-07-26 Юніверсіті Оф Лестер СПОСІБ ПРОФІЛАКТИКИ АБО ЗМЕНШЕННЯ УРАЖЕННЯ НИРОК У СУБ'ЄКТА, ЩО СТРАЖДАЄ НА СТЕРОЇДЗАЛЕЖНУ ІМУНОГЛОБУЛІН-А-НЕФРОПАТІЮ (IgAN)
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
WO2019221516A1 (ko) * 2018-05-16 2019-11-21 주식회사 지놈앤컴퍼니 Lrit2 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
WO2020186256A1 (en) * 2019-03-14 2020-09-17 Aravive Inc Methods of treating immunoglobulin a nephropathy (igan) using axl decoy receptors
WO2021026476A1 (en) * 2019-08-08 2021-02-11 Mpeg La, L.L.C. Complement targeting with multimeric oligonucleotides
CN115335077A (zh) * 2019-11-26 2022-11-11 奥默罗斯公司 用于治疗和/或预防与造血干细胞移植相关的特发性肺炎综合征（ips）和/或毛细血管渗漏综合征（cls）和/或植入综合征（es）和/或液体超负荷（fo）的方法
BR112022010881A2 (pt) 2019-12-04 2022-08-23 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
BR112022010890A2 (pt) 2019-12-04 2022-08-16 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules
CN116615544A (zh) * 2021-12-10 2023-08-18 舒泰神（北京）生物制药股份有限公司 特异性识别masp2的抗体及其应用
WO2023225163A1 (en) * 2022-05-19 2023-11-23 Chinook Therapeutics, Inc. Methods of treating focal segmental glomerulosclerosis with atrasentan

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
RO114469B1 (ro) 1987-12-15 1999-04-30 Gene Shears Pty Ltd Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
JP4723244B2 (ja) 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
PL1625166T3 (pl) 2003-05-12 2015-08-31 Helion Biotech Aps Przeciwciała przeciwko masp-2
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) * 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
CA2777845C (en) 2009-10-16 2017-08-01 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US9102721B2 (en) 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
WO2012139081A2 (en) * 2011-04-08 2012-10-11 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US9011860B2 (en) * 2011-05-04 2015-04-21 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
RS61755B1 (sr) * 2012-06-18 2021-05-31 Omeros Corp Kompozicije i postupci za inhibiciju masp-1 i/ili masp-2 i/ili masp-3 za tretman različitih bolesti i poremećaja
NZ629682A (en) * 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
IL283373B1 (en) 2013-10-17 2024-04-01 Omeros Corp Pharmaceutical preparations containing MASP-2 suppressors to suppress MASP-2-dependent complement activation and related diseases
UA127339C2 (uk) 2016-01-05 2023-07-26 Юніверсіті Оф Лестер СПОСІБ ПРОФІЛАКТИКИ АБО ЗМЕНШЕННЯ УРАЖЕННЯ НИРОК У СУБ'ЄКТА, ЩО СТРАЖДАЄ НА СТЕРОЇДЗАЛЕЖНУ ІМУНОГЛОБУЛІН-А-НЕФРОПАТІЮ (IgAN)
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
KR101930345B1 (ko) * 2016-12-20 2019-03-11 김은진 지혈제 조성물

Also Published As

Publication number Publication date
JP2020114845A (ja) 2020-07-30
CL2018001817A1 (es) 2019-01-11
IL294411A (en) 2022-08-01
JP2019504880A (ja) 2019-02-21
US20170189525A1 (en) 2017-07-06
MA43591A (fr) 2021-05-26
BR112018013723A2 (pt) 2018-12-26
CA3185172A1 (en) 2017-07-13
EP3400012A4 (en) 2019-12-11
US20210077621A1 (en) 2021-03-18
SG11201805695SA (en) 2018-07-30
MX2018008331A (es) 2019-05-30
CA3010593C (en) 2024-02-13
JP7430208B2 (ja) 2024-02-09
CL2020002444A1 (es) 2021-02-19
KR20200116175A (ko) 2020-10-08
IL260430B1 (ru) 2023-02-01
SG10202001580SA (en) 2020-04-29
CL2019001411A1 (es) 2019-08-02
ZA201805238B (en) 2023-05-31
IL260430A (ru) 2018-08-30
AU2017205453B2 (en) 2020-03-12
AU2020201804A1 (en) 2020-03-26
CA3010593A1 (en) 2017-07-13
KR20180096794A (ko) 2018-08-29
MY194810A (en) 2022-12-16
UA127339C2 (uk) 2023-07-26
AU2020201804B2 (en) 2022-06-16
JP2022065145A (ja) 2022-04-26
GEP20217290B (en) 2021-09-10
KR102564616B1 (ko) 2023-08-08
US10736960B2 (en) 2020-08-11
MX2023007754A (es) 2023-07-07
EP3400012A1 (en) 2018-11-14
WO2017120344A1 (en) 2017-07-13
CN114306593A (zh) 2022-04-12
KR20220011791A (ko) 2022-01-28
KR102475622B1 (ko) 2022-12-08
NZ744629A (en) 2020-06-26
KR20230080493A (ko) 2023-06-07
CN117503923A (zh) 2024-02-06
CN108495652A (zh) 2018-09-04
JP6682653B2 (ja) 2020-04-15
AU2017205453A1 (en) 2018-08-16
AU2022221419A1 (en) 2022-11-10
KR102528260B1 (ko) 2023-05-04
AU2022203914A1 (en) 2022-06-23
PH12018501435A1 (en) 2019-03-04
IL260430B2 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
EA201891570A1 (ru) Способ подавления фиброза у нуждающегося в этом субъекта
PH12018502046A1 (en) Methods for inhibiting angiogenesis in a subject in need thereof
CY1123776T1 (el) Μεθοδοι για την αντιμετωπιση καταστασεων που συνδεονται με την ενεργοποιηση συμπληρωματος εξαρτωμενου απο την μasp-2
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
CY1118696T1 (el) Μεθοδοι για θεραπεια διαχυτης ενδοαγγειακης πηξης με παρεμποδιση εξαρτωμενης απο masp-2 ενεργοποιησης συμπληρωματος
EA201791243A1 (ru) Лечение пузырчатки
EA201891132A1 (ru) Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента
DOP2018000014A (es) Anticuerpos que se unen a la sortilina e inhiben la vinculación de progranulina
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
PH12019500711A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
EA201791937A1 (ru) Противовоспалительные полипептиды
MX2019002149A (es) Metodo para el tratamiento de prurito y/o comezon.
EA202191311A1 (ru) Способ подавления фиброза у нуждающегося в этом субъекта
EA201990903A1 (ru) Способ уменьшения протеинурии у человека, страдающего от иммуноглобулин а нефропатии
BR112018070526A2 (pt) tratamento do carcinoma de células renais com lenvatinibe e everolimo
ZA202102023B (en) Potentiation of helminth treatment
MX2022007453A (es) Potenciacion de tratamiento contra helmintos.
Houston et al. Effects of Memantine and Oleocanthal on Alzheimer's Disease
MA42711B1 (fr) Méthodes de traitement d'états pathologiques associés à une activation du complément dépendant de masp-2
EA202090453A3 (ru) Антитела к cd40
NZ629683A (en) Methods for treating conditions associated with masp-2 dependent complement activation